8-methyl-4-[4-(2-oxo-2-piperidin-1-ylethoxy)phenyl]-7-pyrrolidin-1-yl-3,4-dihydro-1H-quinolin-2-one
C27H33N3O3 — CID 171908857
Data last refreshed: (MolForge compound catalog, from PubChem)
About 8-methyl-4-[4-(2-oxo-2-piperidin-1-ylethoxy)phenyl]-7-pyrrolidin-1-yl-3,4-dihydro-1H-quinolin-2-one
8-methyl-4-[4-(2-oxo-2-piperidin-1-ylethoxy)phenyl]-7-pyrrolidin-1-yl-3,4-dihydro-1H-quinolin-2-one (PubChem CID 171908857) has the molecular formula C27H33N3O3 and a molecular weight of 447.58 g/mol. Its IUPAC name is 8-methyl-4-[4-(2-oxo-2-piperidin-1-ylethoxy)phenyl]-7-pyrrolidin-1-yl-3,4-dihydro-1H-quinolin-2-one.
Molecular Properties
| Compound Name | 8-methyl-4-[4-(2-oxo-2-piperidin-1-ylethoxy)phenyl]-7-pyrrolidin-1-yl-3,4-dihydro-1H-quinolin-2-one |
|---|---|
| PubChem CID | 171908857 |
| Molecular Formula | C27H33N3O3 |
| Molecular Weight | 447.58 g/mol |
| Exact Mass | 447.25 |
| IUPAC Name | 8-methyl-4-[4-(2-oxo-2-piperidin-1-ylethoxy)phenyl]-7-pyrrolidin-1-yl-3,4-dihydro-1H-quinolin-2-one |
| SMILES | Cc1c(N2CCCC2)ccc2c1NC(=O)CC2c1ccc(OCC(=O)N2CCCCC2)cc1 |
| InChI | InChI=1S/C27H33N3O3/c1-19-24(29-13-5-6-14-29)12-11-22-23(17-25(31)28-27(19)22)20-7-9-21(10-8-20)33-18-26(32)30-15-3-2-4-16-30/h7-12,23H,2-6,13-18H2,1H3,(H,28,31) |
| InChIKey | ZPEDGWBSRUTOTP-UHFFFAOYSA-N |
| XLogP | 4.46 |
| TPSA | 61.88 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 4 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 33 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 447.58 |
| LogP ≤ 5 | 4.46 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 4 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 171908857 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.